Stereospecific analysis and enantiomeric disposition of 3,4- methylenedioxymethamphetamine (ecstasy) in humans

Clinical Chemistry

Volumn 45, Issue 7, 1999, Pages 1058-1069

  Fallon, John K ^a   Kicman, Andrew T ^a   Henry, John A ^b   Milligan, Peter J ^a   Cowan, David A ^a   Hutt, Andrew J ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b ST MARY S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

3,4 METHYLENEDIOXYAMPHETAMINE; 3,4 METHYLENEDIOXYMETHAMPHETAMINE;

AREA UNDER THE CURVE; ARTICLE; DRUG DETERMINATION; DRUG DISPOSITION; ENANTIOMER; HUMAN; MALE; MATHEMATICAL MODEL; NORMAL HUMAN; PLASMA HALF LIFE; RACEMIC MIXTURE; STEREOSPECIFICITY;

EID: 0032779463     PISSN: 00099147     EISSN: None     Source Type: Journal    
DOI: 10.1093/clinchem/45.7.1058     Document Type: Article

References (35)

1. Nichols DE, Oberlander R. Structure-activity relationships of MDMA-like substances. Research monograph 94, Rockville, MD: National Institute on Drug Abuse, 1989:1-29.
2. Well A. The love drug. J Psychedelic Drugs 1976;8:335-7.
3. Vereby K, Alrazi J, Jaffe JH. The complications of "Ecstasy" (MDMA). JAMA 1988;259:1649-50.
4. Climko RP, Roehrich H, Sweeney OR, Al-Razi J. Ecstasy: a review of MDMA and MDA. Int J Psychiatry Med 1986;16:359-72.
5. Steele T, McCann UD, Ricaurte GA. 3,4-Methylenedioxymethamphetamine (MDMA, "Ecstasy"): pharmacology and toxicology in animals and humans. Addiction 1994;89:539-51.
6. Milroy CM, Clark JC, Forrest ARW. Pathology and deaths associated with "ecstasy" and "eve" misuse. J Clin Pathol 1996;49:149-53.
7. Drug Enforcement Administration. Microgram XXVIII (8). Washington, DC: Drug Enforcement Administration, 1995:235.
8. Henry JA, Fallon JK, Kicman AT, Hutt AJ, Cowan DA, Forsling M. Low dose MDMA ("Ecstasy") Induces vasopressin secretion. Lancet 1998;351:1784.
9. Henry JA, Jeffreys KJ, Dawling S. Toxicity and deaths from 3,4-methylenedioxymethamphetamine ("ecstasy"). Lancet 1992;340:384-7.
10. Dowling GP, McDonough ET III, Bost RO. "Eve" and "Ecstasy". A report of five deaths associated with the use of MDEA and MDMA. JAMA 1987;257:1615-7.
11. Green RA, Goodwin GM. Ecstasy and neurodegeneration. Br Med J 1996;312:1493-4.
12. Anderson GM III, Braun G, Braun U, Nichols DE, Shulgin AT. Absolute configuration and psychotomimetic activity. Research monograph 22. Rockville, MD: National Institute on Drug Abuse, 1978:8-15.
13. Fitzgerald RL, Blanke RV, Poklis A. Stereoselective pharmacokinetics of 3,4-methylenedioxymethamphetamine in the rat. Chirality 1990;2:241-8.
14. Moore KA, Mozayani A, Fierro MF, Poklis A. Distribution of 3,4-methylenedioxymethamphetamine (MDMA) and 3,4-methylenedioxyamphetamine (MDA) stereoisomers in a fatal poisoning. Forensic Sci Int 1996;83:111-9.
15. De Boer D, Tan LP, Gorter P, Van de Wal RMA, Kettenes-van den Bosch JJ, De Bruijn EA, Maes RAA. Gas chromatographic/mass spectrometric assay for profiling the enantiomers of 3,4-methylenedioxymethamphetamine and its chiral metabolites using positive chemical ionization ion trap mass spectrometry. J Mass Spectrom 1997;32:1236-46.
16. Lanz M, Brenneisen R, Thormann W. Enantioselective determinetion of 3,4-methylenedioxymethamphatamine and two of its metabolites in human urine by cyclodextrin-modified capillary zone electrophoresis. Electrophoresis 1997;18:1035-43.
17. Helmlin HJ, Bracher K, Bourquin D, Vonlanthen D, Brenneisen R. Analysis of 3,4-methylenedioxymethamphetemine (MDMA) and its metabolites in plasma and urine by HPLC-DAD and GC-MS. J Anal Toxicol 1996;20:432-40.
18. Rizzi AM, Hirz R, Cladrowa-Runge S, Jonsson H. Enantiomeric separation of amphetamine, methamphetamine and ring substituted amphetamines by means of a β-cyclodextrin-chiral stationary phase. Chromatographia 1994;39:131-7.
19. Tagliaro F, Manetto G, Bellini S, Scarcella D, Smith FP, Marigo M. Simultaneous chiral separation of 3,4-methylenedioxymethamphetamine, 3,4-methylenedioxyamphetamine, 3,4-methylenedioxyethylamphetamine, ephedrine, amphetamine and methamphetamine by capillary electrophoresis in uncoated and coated capillaries with native beta-cyclodextrin as the chiral selector: preliminary application to the analysis of urine and hair. Electrophoresis 1998;19:42-50.
20. Fitzgerald RL, Blanke RV, Glennon RA, Yousif MY, Rosecrans JA, Poklis A. Determination of 3,4-methylenedioxyamphetamine and 3,4-methylenedioxymethamphetamine enantiomers in whole blood. J Chromatogr B 1989;490:59-69.
21. Hegadoren KM, Baker GB, Coutts RT. The simultaneous separation and quantitation of the enantiomers of MDMA and MDA using gas chromatography with nitrogen-phosphorous detection. Res Commun Subst Abuse 1993;14:67-80.
22. Lim HK, Su Z, Foltz RL. Stereoselective disposition: enantioselective quantitation of 3,4-(methylenedioxy)methamphetamine and three of its metabolites by gas chromatography/electron capture negative ion chemical ionization mass spectrometry. Biol Mass Spectrom 1993;22:403-11.
23. Nichols DE, Barfknecht CF, Rusterholz DB. Asymmetric synthesis of psychotomimetic phenylisopropylamines. J Med Chem 1973;16:480-3.
24. Gal J. Stereoisomer separations via derivatization with optically active reagents. LC-GC 1987;5:106-26.
25. Bonner WA. The adaptation of diastereomeric S-prolyl dipeptide derivatives to the quantitative estimation of R- and S-leucine enantiomers. J Chromatogr Sci 1972;10:159-64.
26. Payan IL, Cadilla-Perezrios R, Fisher R, Man EH. Analysis of problems encountered in the determination of amino acid enantiomeric ratios by gas chromatography. Anal Biochem 1985;149:484-91.
27. Silber B, Riegelman S. Stereospecific assay for (-) and (+) propranolol in human and dog plasma. J Pharmacol Exp Ther 1980;215:643-8.
28. Dale JA, Dull DL, Mosher HS. α-Methoxy-α-trifluoromethylphenylacetic acid, a versatile reagent for the determination of enantiomeric composition of alcohols and amines. J Org Chem 1969;34:2543-9.
29. Cho AK, Hiramatsu M, DiStefano EW, Chang AS, Jenden DJ. Stereochemicai differences in the metabolism of 3,4-methylenedioxymethamphetamine in vivo and in vitro: a pharmacokinetic analysis. Drug Metab Dispos 1990;18:686-91.
30. Singh A. Ecstasy and Prozac. New Scientist 1995;1999:51.
31. Tucker GT, Lennard MS, Ellis SW, Woods HF, Cho AK, Lin LY, et al. The demethylation of methylenedioxymethamphetamine ("Ecstasy") by debrisoquine hydroxylase (CYP2D6). Biochem Pharmacol 1994;47:1151-6.
32. Lin LY, DiStefano EW, Schmitz DA, Hsu L, Ellis SW, Lennard MS, et al. Oxidation of methamphetamine and methylenedioxymethamphetamine by CYP2D6. Drug Metab Dispos 1997;25:1059-64.
33. Fitzgerald RL, Rames JM Jr, Bogema SC, Poklis A. Resolution of methamphetamine stereoisomers in urine drug testing: urinary excretion of R-(-)-methamphetamine following use of nasal inhalers. J Anal Toxicol 1988;12:255-9.
34. Stead AH. The use of pharmacokinetics and drug-metabolism data in forensic toxicology. In: Bridges JW, Chasseaud LF, eds. Progress in drug metabolism, Vol. 9. London: Taylor & Francis, 1986:175-237.
35. Robinson AE, McDowall RD. The distribution of amylobarbitone, butobarbitone, pentobarbitone and quinalbarbitone and hydroxylated metabolites in man. J Pharm Pharmacol 1979;31:357-65.